InSite Vision News

InSite Vision Incorporated , a company developing ophthalmic products for unmet eye care needs, today announced that the companya s Annual Meeting of Stockholders will be held at 10:00 a.m. Pacific Time on Wednesday, December 16, 2009.

InSite Vision Incorporated today announced that Inspire Pharmaceuticals, its commercial partner for AzaSite 1% in the U.S and Canada, has committed to increasing production of AzaSite in response to the manufacturing supply shortage of erythromycin ophthalmic ointment .

InSite Vision Inc. , an Alameda drug developer that has lost nearly $24.4 million since 2004, has been removed from the American Stock Exchange.

Main Category: Eye Health / Blindness Also Included In: Regulatory Affairs / Drug Approvals Article Date: 04 Jun 2009 InSite Vision Incorporated announced that Bausch & Lomb has received approval of Besivance 0.6% for the treatment of bacterial conjunctivitis in patients one year and older from the U.S. Food and Drug Administration .